Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Status:
Terminated
Trial end date:
2018-03-08
Target enrollment:
Participant gender:
Summary
Patients with previously treated multiple myeloma and kidney dysfunction will be treated with
lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of
lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe
and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will
study how well the the treatment works in patients with previously treated (relapsed or
refractory) multiple myeloma and kidney dysfunction.
Biological therapies, such as lenalidomide, may stimulate the immune system in different ways
and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more
cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have
changes in their kidney function.